Literature DB >> 7560168

OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed and paraffin wax embedded material.

C Edwards1, J Oates.   

Abstract

AIMS: To investigate the reaction of antibodies OV 632 and MOC 31 in paraffin wax sections as opposed to frozen sections and cytological preparations; to evaluate their usefulness in the differential diagnosis of malignant mesothelioma and secondary adenocarcinoma of the pleura; and to assess the efficacy of microwave pretreatment of sections in unmasking their associated epitopes.
METHODS: Immunohistochemistry, using a standard avidin-biotin technique, with microwave pretreatment and trypsinisation in a certain proportion of cases. The material comprised 43 mesotheliomas, 44 adenocarcinomas and five reactive pleuras.
RESULTS: Epithelial mesotheliomas and the hyperplastic mesothelial cells reacted strongly with OV 632, the reaction with sarcomatoid and desmoplastic tumours was weak, and the reaction with adenocarcinomas was variable. An unequivocal but sometimes patchy positive reaction was obtained with MOC 31 in all but one of the adenocarcinomas; all but one of the mesotheliomas and all the reactive pleuras were negative. Review of the two apparently anomalous cases revealed that the original diagnoses had probably been incorrect. Reactions to both antibodies were abolished by microwave pretreatment, and also by prior trypsinisation in the case of OV 632.
CONCLUSIONS: OV 632 is unsuitable for routine clinical use in paraffin wax embedded material. MOC 31, however, would be a useful addition to a panel of antibodies in the differential diagnosis of mesothelioma and adenocarcinoma in large biopsy and resection specimens and necropsy material. Its value in small biopsy specimens remains to be assessed. Microwave pretreatment does not enhance the reactions with either antibody.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7560168      PMCID: PMC502712          DOI: 10.1136/jcp.48.7.626

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  12 in total

Review 1.  Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma.

Authors:  K Sheibani; J M Esteban; A Bailey; H Battifora; L M Weiss
Journal:  Hum Pathol       Date:  1992-02       Impact factor: 3.466

Review 2.  Pathology of human mesothelioma. Etiologic and diagnostic considerations.

Authors:  V L Roggli; J Kolbeck; F Sanfilippo; J D Shelburne
Journal:  Pathol Annu       Date:  1987

3.  The search for the optimal immunohistochemical panel for the diagnosis of malignant mesothelioma.

Authors:  L M Weiss; H Battifora
Journal:  Hum Pathol       Date:  1993-04       Impact factor: 3.466

4.  Immunocytology of body cavity fluids. MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells.

Authors:  T Ruitenbeek; A S Gouw; S Poppema
Journal:  Arch Pathol Lab Med       Date:  1994-03       Impact factor: 5.534

5.  Pleural malignant mesothelioma following Wilms' tumor.

Authors:  M B Austin; R E Fechner; V L Roggli
Journal:  Am J Clin Pathol       Date:  1986-08       Impact factor: 2.493

6.  Immunohistological characterization of a monoclonal antibody (OV632) against epithelial ovarian carcinomas.

Authors:  G J Fleuren; E G Coerkamp; M Nap; L J vd Broek; S O Warnaar
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

Review 7.  Pseudomesotheliomatous adenocarcinoma: a reappraisal.

Authors:  M Koss; W Travis; C Moran; L Hochholzer
Journal:  Semin Diagn Pathol       Date:  1992-05       Impact factor: 3.464

8.  Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma.

Authors:  R W Brown; G M Clark; A K Tandon; D C Allred
Journal:  Hum Pathol       Date:  1993-04       Impact factor: 3.466

9.  Immunocytochemistry in the differential diagnosis of effusions: use of logistic regression to select a panel of antibodies to distinguish adenocarcinomas from mesothelial proliferations.

Authors:  D M Frisman; W F McCarthy; P Schleiff; S B Buckner; J D Nocito; T J O'Leary
Journal:  Mod Pathol       Date:  1993-03       Impact factor: 7.842

10.  Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma.

Authors:  M Delahaye; H C Hoogsteden; T H Van der Kwast
Journal:  J Pathol       Date:  1991-10       Impact factor: 7.996

View more
  4 in total

1.  Immunophenotypings of malignant epithelial mesothelioma and their roles in the differential diagnosis.

Authors:  Qiurong Ruan; Yuchang Hu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2004

2.  HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura.

Authors:  A D Kennedy; G King; K M Kerr
Journal:  J Clin Pathol       Date:  1997-10       Impact factor: 3.411

3.  Specificity of MOC-31 and HBME-1 immunohistochemistry in the differential diagnosis of adenocarcinoma and malignant mesothelioma: a study on environmental malignant mesothelioma cases from Turkish villages.

Authors:  Derya Gümürdülü; E Handan Zeren; Philip T Cagle; Fazilet Kayasel uk; Nazan Alparslan; Ali Kocabas; Ilhan Tuncer
Journal:  Pathol Oncol Res       Date:  2003-01-06       Impact factor: 3.201

4.  Comparison of DNA copy number changes in malignant mesothelioma, adenocarcinoma and large-cell anaplastic carcinoma of the lung.

Authors:  A M Björkqvist; L Tammilehto; S Nordling; M Nurminen; S Anttila; K Mattson; S Knuutila
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.